ID   MBOA5_HUMAN             Reviewed;         487 AA.
AC   Q6P1A2; B2RDH0; B7Z3N3; Q7KZS1; Q92980; Q9BW40;
DT   02-MAY-2006, integrated into UniProtKB/Swiss-Prot.
DT   05-JUL-2004, sequence version 1.
DT   18-JUN-2025, entry version 166.
DE   RecName: Full=Lysophospholipid acyltransferase 5;
DE            Short=LPLAT 5;
DE            EC=2.3.1.- {ECO:0000269|PubMed:18195019, ECO:0000269|PubMed:18772128, ECO:0000269|PubMed:18782225};
DE   AltName: Full=1-acylglycerophosphocholine O-acyltransferase;
DE            EC=2.3.1.23 {ECO:0000269|PubMed:18195019, ECO:0000269|PubMed:18772128, ECO:0000269|PubMed:18782225};
DE   AltName: Full=1-acylglycerophosphoethanolamine O-acyltransferase;
DE            EC=2.3.1.n7 {ECO:0000269|PubMed:18772128, ECO:0000269|PubMed:18782225};
DE   AltName: Full=1-acylglycerophosphoserine O-acyltransferase;
DE            EC=2.3.1.n6 {ECO:0000269|PubMed:18195019, ECO:0000269|PubMed:18772128, ECO:0000269|PubMed:18782225};
DE   AltName: Full=Lysophosphatidylcholine acyltransferase;
DE            Short=LPCAT;
DE            Short=Lyso-PC acyltransferase;
DE   AltName: Full=Lysophosphatidylcholine acyltransferase 3;
DE            Short=Lyso-PC acyltransferase 3;
DE   AltName: Full=Lysophosphatidylserine acyltransferase;
DE            Short=LPSAT;
DE            Short=Lyso-PS acyltransferase;
DE   AltName: Full=Membrane-bound O-acyltransferase domain-containing protein 5;
DE            Short=O-acyltransferase domain-containing protein 5;
GN   Name=LPCAT3; Synonyms=MBOAT5, OACT5;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Endometrium;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M., Kovar-Smith C.,
RA   Lewis L.R., Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R.,
RA   Montgomery K.T., Morgan M.B., Nazareth L.V., Scott G., Sodergren E.,
RA   Song X.-Z., Steffen D., Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y.,
RA   Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G.,
RA   Chen Z., Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H.,
RA   Draper H., Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S.,
RA   Kelly S.H., Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M.,
RA   Nguyen B.-V., Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H.,
RA   Santibanez J., Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q.,
RA   Williams G.A., Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V.,
RA   Bailey M., Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E.,
RA   Burkett C.E., Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M., Dathorne S.R.,
RA   David R., Davis C.M., Davy-Carroll L., Deshazo D.R., Donlin J.E.,
RA   D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J., Escotto M., Flagg N.,
RA   Forbes L.D., Gabisi A.M., Garza M., Hamilton C., Henderson N.,
RA   Hernandez O., Hines S., Hogues M.E., Huang M., Idlebird D.G., Johnson R.,
RA   Jolivet A., Jones S., Kagan R., King L.M., Leal B., Lebow H., Lee S.,
RA   LeVan J.M., Lewis L.C., London P., Lorensuhewa L.M., Loulseged H.,
RA   Lovett D.A., Lucier A., Lucier R.L., Ma J., Madu R.C., Mapua P.,
RA   Martindale A.D., Martinez E., Massey E., Mawhiney S., Meador M.G.,
RA   Mendez S., Mercado C., Mercado I.C., Merritt C.E., Miner Z.L., Minja E.,
RA   Mitchell T., Mohabbat F., Mohabbat K., Montgomery B., Moore N., Morris S.,
RA   Munidasa M., Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O.,
RA   Nwokenkwo S., Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D., Trejos Z.Y.,
RA   Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I., Vera V.A.,
RA   Villasana D.M., Wang L., Ward-Moore S., Warren J.T., Wei X., White F.,
RA   Williamson A.L., Wleczyk R., Wooden H.S., Wooden S.H., Yen J., Yoon L.,
RA   Yoon V., Zorrilla S.E., Nelson D., Kucherlapati R., Weinstock G.,
RA   Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [4] {ECO:0000312|EMBL:AAH65194.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Colon {ECO:0000312|EMBL:AAH00664.2}, and Pancreas
RC   {ECO:0000312|EMBL:AAH65194.1};
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5] {ECO:0000305, ECO:0000312|EMBL:AAC51640.1}
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 50-487 (ISOFORM 1).
RX   PubMed=9074930; DOI=10.1101/gr.7.3.268;
RA   Ansari-Lari M.A., Shen Y., Muzny D.M., Lee W., Gibbs R.A.;
RT   "Large-scale sequencing in human chromosome 12p13: experimental and
RT   computational gene structure determination.";
RL   Genome Res. 7:268-280(1997).
RN   [6] {ECO:0000305, ECO:0000312|EMBL:AAP35646.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 107-487 (ISOFORM 1/2).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=18782225; DOI=10.1111/j.1365-2443.2008.01212.x;
RA   Matsuda S., Inoue T., Lee H.C., Kono N., Tanaka F., Gengyo-Ando K.,
RA   Mitani S., Arai H.;
RT   "Member of the membrane-bound O-acyltransferase (MBOAT) family encodes a
RT   lysophospholipid acyltransferase with broad substrate specificity.";
RL   Genes Cells 13:879-888(2008).
RN   [8]
RP   IDENTIFICATION, FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION,
RP   BIOPHYSICOCHEMICAL PROPERTIES, PATHWAY, AND TISSUE SPECIFICITY.
RX   PubMed=18195019; DOI=10.1074/jbc.m710422200;
RA   Zhao Y., Chen Y.Q., Bonacci T.M., Bredt D.S., Li S., Bensch W.R.,
RA   Moller D.E., Kowala M., Konrad R.J., Cao G.;
RT   "Identification and characterization of a major liver
RT   lysophosphatidylcholine acyltransferase.";
RL   J. Biol. Chem. 283:8258-8265(2008).
RN   [9]
RP   FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, TISSUE SPECIFICITY, AND
RP   SUBSTRATE SPECIFICITY.
RX   PubMed=18772128; DOI=10.1074/jbc.m806194200;
RA   Gijon M.A., Riekhof W.R., Zarini S., Murphy R.C., Voelker D.R.;
RT   "Lysophospholipid acyltransferases and arachidonate recycling in human
RT   neutrophils.";
RL   J. Biol. Chem. 283:30235-30245(2008).
RN   [10]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
CC   -!- FUNCTION: Lysophospholipid O-acyltransferase (LPLAT) that catalyzes the
CC       reacylation step of the phospholipid remodeling process also known as
CC       the Lands cycle (PubMed:18195019, PubMed:18772128, PubMed:18782225).
CC       Catalyzes transfer of the fatty acyl chain from fatty acyl-CoA to 1-
CC       acyl lysophospholipid to form various classes of phospholipids.
CC       Converts 1-acyl lysophosphatidylcholine (LPC) into phosphatidylcholine
CC       (PC) (LPCAT activity), 1-acyl lysophosphatidylserine (LPS) into
CC       phosphatidylserine (PS) (LPSAT activity) and 1-acyl
CC       lysophosphatidylethanolamine (LPE) into phosphatidylethanolamine (PE)
CC       (LPEAT activity) (PubMed:18195019, PubMed:18772128, PubMed:18782225).
CC       Favors polyunsaturated fatty acyl-CoAs as acyl donors compared to
CC       saturated fatty acyl-CoAs (PubMed:18195019, PubMed:18772128). Has
CC       higher activity for LPC acyl acceptors compared to LPEs and LPSs. Can
CC       also transfer the fatty acyl chain from fatty acyl-CoA to 1-O-alkyl
CC       lysophospholipid or 1-O-alkenyl lysophospholipid with lower efficiency
CC       (By similarity). Acts as a major LPC O-acyltransferase in liver and
CC       intestine. As a component of the liver X receptor/NR1H3 or NR1H2
CC       signaling pathway, mainly catalyzes the incorporation of arachidonate
CC       into PCs of endoplasmic reticulum (ER) membranes, increasing membrane
CC       dynamics and enabling triacylglycerols transfer to nascent very low-
CC       density lipoprotein (VLDL) particles. Promotes processing of sterol
CC       regulatory protein SREBF1 in hepatocytes, likely by facilitating the
CC       translocation of SREBF1-SCAP complex from ER to the Golgi apparatus (By
CC       similarity). Participates in mechanisms by which the liver X
CC       receptor/NR1H3 or NR1H2 signaling pathway counteracts lipid-induced ER
CC       stress response and inflammation. Down-regulates hepatic inflammation
CC       by limiting arachidonic acid availability for synthesis of inflammatory
CC       eicosanoids, such as prostaglandins (By similarity). In enterocytes,
CC       acts as a component of a gut-brain feedback loop that coordinates
CC       dietary lipid absorption and food intake. Regulates the abundance of
CC       PCs containing linoleate and arachidonate in enterocyte membranes,
CC       enabling passive diffusion of fatty acids and cholesterol across the
CC       membrane for efficient chylomicron assembly (By similarity). In the
CC       intestinal crypt, acts as a component of dietary-responsive
CC       phospholipid-cholesterol axis, regulating the biosynthesis of
CC       cholesterol and its mitogenic effects on intestinal stem cells (By
CC       similarity). {ECO:0000250|UniProtKB:Q91V01,
CC       ECO:0000269|PubMed:18195019, ECO:0000269|PubMed:18772128,
CC       ECO:0000269|PubMed:18782225}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1-acyl-sn-glycero-3-phosphocholine + an acyl-CoA = a 1,2-
CC         diacyl-sn-glycero-3-phosphocholine + CoA; Xref=Rhea:RHEA:12937,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:57643, ChEBI:CHEBI:58168,
CC         ChEBI:CHEBI:58342; EC=2.3.1.23;
CC         Evidence={ECO:0000269|PubMed:18195019, ECO:0000269|PubMed:18772128,
CC         ECO:0000269|PubMed:18782225};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:12938;
CC         Evidence={ECO:0000305|PubMed:18195019, ECO:0000305|PubMed:18772128,
CC         ECO:0000305|PubMed:18782225};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1-acyl-sn-glycero-3-phosphoethanolamine + an acyl-CoA = a
CC         1,2-diacyl-sn-glycero-3-phosphoethanolamine + CoA;
CC         Xref=Rhea:RHEA:32995, ChEBI:CHEBI:57287, ChEBI:CHEBI:58342,
CC         ChEBI:CHEBI:64381, ChEBI:CHEBI:64612; EC=2.3.1.n7;
CC         Evidence={ECO:0000269|PubMed:18772128, ECO:0000269|PubMed:18782225};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:32996;
CC         Evidence={ECO:0000305|PubMed:18772128, ECO:0000305|PubMed:18782225};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1-acyl-sn-glycero-3-phospho-L-serine + an acyl-CoA = a 1,2-
CC         diacyl-sn-glycero-3-phospho-L-serine + CoA; Xref=Rhea:RHEA:33191,
CC         ChEBI:CHEBI:57262, ChEBI:CHEBI:57287, ChEBI:CHEBI:58342,
CC         ChEBI:CHEBI:64379; EC=2.3.1.n6;
CC         Evidence={ECO:0000269|PubMed:18195019, ECO:0000269|PubMed:18772128,
CC         ECO:0000269|PubMed:18782225};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:33192;
CC         Evidence={ECO:0000305|PubMed:18195019, ECO:0000305|PubMed:18772128,
CC         ECO:0000305|PubMed:18782225};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(9Z,12Z)-octadecadienoyl-CoA + a 1-acyl-sn-glycero-3-
CC         phosphocholine = 1-acyl-2-(9Z,12Z)-octadecadienoyl-sn-glycero-3-
CC         phosphocholine + CoA; Xref=Rhea:RHEA:37563, ChEBI:CHEBI:57287,
CC         ChEBI:CHEBI:57383, ChEBI:CHEBI:58168, ChEBI:CHEBI:60000;
CC         Evidence={ECO:0000269|PubMed:18782225};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37564;
CC         Evidence={ECO:0000305|PubMed:18782225};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoyl-CoA + a 1-acyl-sn-glycero-3-
CC         phosphocholine = 1-acyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-
CC         glycero-3-phosphocholine + CoA; Xref=Rhea:RHEA:37559,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:57368, ChEBI:CHEBI:58168,
CC         ChEBI:CHEBI:75063; Evidence={ECO:0000269|PubMed:18782225};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37560;
CC         Evidence={ECO:0000305|PubMed:18782225};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=dodecanoyl-CoA + 1-hexadecanoyl-sn-glycero-3-phosphocholine =
CC         1-hexadecanoyl-2-dodecanoyl-sn-glycero-3-phosphocholine + CoA;
CC         Xref=Rhea:RHEA:37515, ChEBI:CHEBI:57287, ChEBI:CHEBI:57375,
CC         ChEBI:CHEBI:72998, ChEBI:CHEBI:75018;
CC         Evidence={ECO:0000269|PubMed:18195019};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37516;
CC         Evidence={ECO:0000305|PubMed:18195019};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=octadecanoyl-CoA + 1-hexadecanoyl-sn-glycero-3-phosphocholine
CC         = 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine + CoA;
CC         Xref=Rhea:RHEA:35987, ChEBI:CHEBI:57287, ChEBI:CHEBI:57394,
CC         ChEBI:CHEBI:72998, ChEBI:CHEBI:73000;
CC         Evidence={ECO:0000269|PubMed:18195019};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:35988;
CC         Evidence={ECO:0000305|PubMed:18195019};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-dodecanoyl-sn-glycero-3-phosphocholine + hexadecanoyl-CoA =
CC         1-dodecanoyl-2-hexadecanoyl-sn-glycero-3-phosphocholine + CoA;
CC         Xref=Rhea:RHEA:37511, ChEBI:CHEBI:57287, ChEBI:CHEBI:57379,
CC         ChEBI:CHEBI:74966, ChEBI:CHEBI:75017;
CC         Evidence={ECO:0000269|PubMed:18195019};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37512;
CC         Evidence={ECO:0000305|PubMed:18195019};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-tetradecanoyl-sn-glycero-3-phosphocholine + hexadecanoyl-CoA
CC         = 1-tetradecanoyl-2-hexadecanoyl-sn-glycero-3-phosphocholine + CoA;
CC         Xref=Rhea:RHEA:37655, ChEBI:CHEBI:57287, ChEBI:CHEBI:57379,
CC         ChEBI:CHEBI:64489, ChEBI:CHEBI:75062;
CC         Evidence={ECO:0000269|PubMed:18195019};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37656;
CC         Evidence={ECO:0000305|PubMed:18195019};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-hexadecanoyl-sn-glycero-3-phosphocholine + hexadecanoyl-CoA
CC         = 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine + CoA;
CC         Xref=Rhea:RHEA:35983, ChEBI:CHEBI:57287, ChEBI:CHEBI:57379,
CC         ChEBI:CHEBI:72998, ChEBI:CHEBI:72999;
CC         Evidence={ECO:0000269|PubMed:18195019};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:35984;
CC         Evidence={ECO:0000305|PubMed:18195019};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-octadecanoyl-sn-glycero-3-phosphocholine + hexadecanoyl-CoA
CC         = 1-octadecanoyl-2-hexadecanoyl-sn-glycero-3-phosphocholine + CoA;
CC         Xref=Rhea:RHEA:37527, ChEBI:CHEBI:57287, ChEBI:CHEBI:57379,
CC         ChEBI:CHEBI:73858, ChEBI:CHEBI:75026;
CC         Evidence={ECO:0000269|PubMed:18195019};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37528;
CC         Evidence={ECO:0000305|PubMed:18195019};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine +
CC         hexadecanoyl-CoA = 1-(9Z-octadecenoyl)-2-hexadecanoyl-sn-glycero-3-
CC         phosphocholine + CoA; Xref=Rhea:RHEA:37383, ChEBI:CHEBI:28610,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:57379, ChEBI:CHEBI:74667;
CC         Evidence={ECO:0000269|PubMed:18195019, ECO:0000269|PubMed:18772128};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37384;
CC         Evidence={ECO:0000305|PubMed:18195019, ECO:0000305|PubMed:18772128};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(9Z)-hexadecenoyl-CoA + 1-hexadecanoyl-sn-glycero-3-
CC         phosphocholine = 1-hexadecanoyl-2-(9Z-hexadecenoyl)-sn-glycero-3-
CC         phosphocholine + CoA; Xref=Rhea:RHEA:37207, ChEBI:CHEBI:57287,
CC         ChEBI:CHEBI:61540, ChEBI:CHEBI:72998, ChEBI:CHEBI:74000;
CC         Evidence={ECO:0000269|PubMed:18772128};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37208;
CC         Evidence={ECO:0000305|PubMed:18772128};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-hexadecanoyl-sn-glycero-3-phosphocholine + (9Z)-
CC         octadecenoyl-CoA = 1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-
CC         phosphocholine + CoA; Xref=Rhea:RHEA:35991, ChEBI:CHEBI:57287,
CC         ChEBI:CHEBI:57387, ChEBI:CHEBI:72998, ChEBI:CHEBI:73001;
CC         Evidence={ECO:0000269|PubMed:18195019, ECO:0000269|PubMed:18772128};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:35992;
CC         Evidence={ECO:0000305|PubMed:18195019, ECO:0000305|PubMed:18772128};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(9Z,12Z)-octadecadienoyl-CoA + 1-hexadecanoyl-sn-glycero-3-
CC         phosphocholine = 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-
CC         glycero-3-phosphocholine + CoA; Xref=Rhea:RHEA:35995,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:57383, ChEBI:CHEBI:72998,
CC         ChEBI:CHEBI:73002; Evidence={ECO:0000269|PubMed:18195019,
CC         ECO:0000269|PubMed:18772128};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:35996;
CC         Evidence={ECO:0000305|PubMed:18195019, ECO:0000305|PubMed:18772128};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-dodecanoyl-sn-glycero-3-phosphocholine + (5Z,8Z,11Z,14Z)-
CC         eicosatetraenoyl-CoA = 1-dodecanoyl-2-(5Z,8Z,11Z,14Z)-
CC         eicosatetraenoyl-sn-glycero-3-phosphocholine + CoA;
CC         Xref=Rhea:RHEA:37483, ChEBI:CHEBI:57287, ChEBI:CHEBI:57368,
CC         ChEBI:CHEBI:74966, ChEBI:CHEBI:74967;
CC         Evidence={ECO:0000250|UniProtKB:Q91V01};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37484;
CC         Evidence={ECO:0000250|UniProtKB:Q91V01};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoyl-CoA + 1-hexadecanoyl-sn-
CC         glycero-3-phosphocholine = 1-hexadecanoyl-2-(5Z,8Z,11Z,14Z-
CC         eicosatetraenoyl)-sn-glycero-3-phosphocholine + CoA;
CC         Xref=Rhea:RHEA:35999, ChEBI:CHEBI:57287, ChEBI:CHEBI:57368,
CC         ChEBI:CHEBI:72998, ChEBI:CHEBI:73003;
CC         Evidence={ECO:0000269|PubMed:18195019, ECO:0000269|PubMed:18772128};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:36000;
CC         Evidence={ECO:0000305|PubMed:18195019, ECO:0000305|PubMed:18772128};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-octadecanoyl-sn-glycero-3-phosphocholine + (5Z,8Z,11Z,14Z)-
CC         eicosatetraenoyl-CoA = 1-octadecanoyl-2-(5Z,8Z,11Z,14Z-
CC         eicosatetraenoyl)-sn-glycero-3-phosphocholine + CoA;
CC         Xref=Rhea:RHEA:37479, ChEBI:CHEBI:57287, ChEBI:CHEBI:57368,
CC         ChEBI:CHEBI:73858, ChEBI:CHEBI:74965;
CC         Evidence={ECO:0000250|UniProtKB:Q91V01};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37480;
CC         Evidence={ECO:0000250|UniProtKB:Q91V01};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-eicosanoyl-sn-glycero-3-phosphocholine + (5Z,8Z,11Z,14Z)-
CC         eicosatetraenoyl-CoA = 1-eicosanoyl-2-(5Z,8Z,11Z,14Z)-
CC         eicosatetraenoyl-sn-glycero-3-phosphocholine + CoA;
CC         Xref=Rhea:RHEA:37487, ChEBI:CHEBI:57287, ChEBI:CHEBI:57368,
CC         ChEBI:CHEBI:74968, ChEBI:CHEBI:74970;
CC         Evidence={ECO:0000250|UniProtKB:Q91V01};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37488;
CC         Evidence={ECO:0000250|UniProtKB:Q91V01};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine + (9Z)-
CC         octadecenoyl-CoA = 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-
CC         phosphocholine + CoA; Xref=Rhea:RHEA:37387, ChEBI:CHEBI:28610,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:57387, ChEBI:CHEBI:74669;
CC         Evidence={ECO:0000269|PubMed:18772128};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37388;
CC         Evidence={ECO:0000305|PubMed:18772128};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine + (9Z,12Z)-
CC         octadecadienoyl-CoA = 1-(9Z)-octadecenoyl-2-(9Z,12Z)-octadecadienoyl-
CC         sn-glycero-3-phosphocholine + CoA; Xref=Rhea:RHEA:37391,
CC         ChEBI:CHEBI:28610, ChEBI:CHEBI:57287, ChEBI:CHEBI:57383,
CC         ChEBI:CHEBI:74670; Evidence={ECO:0000269|PubMed:18772128};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37392;
CC         Evidence={ECO:0000305|PubMed:18772128};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine +
CC         (5Z,8Z,11Z,14Z)-eicosatetraenoyl-CoA = 1-(9Z)-octadecenoyl-2-
CC         (5Z,8Z,11Z,14Z)-icosatetraenoyl-sn-glycero-3-phosphocholine + CoA;
CC         Xref=Rhea:RHEA:37395, ChEBI:CHEBI:28610, ChEBI:CHEBI:57287,
CC         ChEBI:CHEBI:57368, ChEBI:CHEBI:74671;
CC         Evidence={ECO:0000269|PubMed:18772128};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37396;
CC         Evidence={ECO:0000305|PubMed:18772128};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1-acyl-sn-glycero-3-phosphoethanolamine + (9Z,12Z)-
CC         octadecadienoyl-CoA = 1-acyl-2-(9Z,12Z)-octadecadienoyl-sn-glycero-3-
CC         phosphoethanolamine + CoA; Xref=Rhea:RHEA:37579, ChEBI:CHEBI:57287,
CC         ChEBI:CHEBI:57383, ChEBI:CHEBI:64381, ChEBI:CHEBI:75069;
CC         Evidence={ECO:0000269|PubMed:18782225};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37580;
CC         Evidence={ECO:0000305|PubMed:18782225};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine +
CC         (9Z,12Z)-octadecadienoyl-CoA = 1-(9Z)-octadecenoyl-2-(9Z,12Z)-
CC         octadecadienoyl-sn-glycero-3-phosphoethanolamine + CoA;
CC         Xref=Rhea:RHEA:37503, ChEBI:CHEBI:57287, ChEBI:CHEBI:57383,
CC         ChEBI:CHEBI:74971, ChEBI:CHEBI:74977;
CC         Evidence={ECO:0000250|UniProtKB:Q91V01};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37504;
CC         Evidence={ECO:0000250|UniProtKB:Q91V01};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-(10Z-heptadecenoyl)-sn-glycero-3-phosphoethanolamine +
CC         (9Z,12Z)-octadecadienoyl-CoA = 1-(10Z-heptadecenoyl)-2-(9Z,12Z-
CC         octadecadienoyl)-sn-glycero-3-phosphoethanolamine + CoA;
CC         Xref=Rhea:RHEA:64228, ChEBI:CHEBI:57287, ChEBI:CHEBI:57383,
CC         ChEBI:CHEBI:149768, ChEBI:CHEBI:149770;
CC         Evidence={ECO:0000250|UniProtKB:Q91V01};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:64229;
CC         Evidence={ECO:0000250|UniProtKB:Q91V01};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1-acyl-sn-glycero-3-phosphoethanolamine + (5Z,8Z,11Z,14Z)-
CC         eicosatetraenoyl-CoA = 1-acyl-2-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-sn-
CC         glycero-3-phosphoethanolamine + CoA; Xref=Rhea:RHEA:37575,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:57368, ChEBI:CHEBI:64381,
CC         ChEBI:CHEBI:75067; Evidence={ECO:0000269|PubMed:18782225};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37576;
CC         Evidence={ECO:0000305|PubMed:18782225};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-hexadecanoyl-sn-glycero-3-phosphoethanolamine +
CC         (5Z,8Z,11Z,14Z)-eicosatetraenoyl-CoA = 1-hexadecanoyl-2-
CC         (5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3-phosphoethanolamine +
CC         CoA; Xref=Rhea:RHEA:36023, ChEBI:CHEBI:57287, ChEBI:CHEBI:57368,
CC         ChEBI:CHEBI:73004, ChEBI:CHEBI:73009;
CC         Evidence={ECO:0000269|PubMed:18772128};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:36024;
CC         Evidence={ECO:0000305|PubMed:18772128};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine +
CC         (5Z,8Z,11Z,14Z)-eicosatetraenoyl-CoA = 1-(9Z)-octadecenoyl-2-
CC         (5Z,8Z,11Z,14Z)-eicosatetraenoyl-sn-glycero-3-phosphoethanolamine +
CC         CoA; Xref=Rhea:RHEA:37495, ChEBI:CHEBI:57287, ChEBI:CHEBI:57368,
CC         ChEBI:CHEBI:74971, ChEBI:CHEBI:74975;
CC         Evidence={ECO:0000250|UniProtKB:Q91V01};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37496;
CC         Evidence={ECO:0000250|UniProtKB:Q91V01};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-(10Z-heptadecenoyl)-sn-glycero-3-phosphoethanolamine +
CC         (5Z,8Z,11Z,14Z)-eicosatetraenoyl-CoA = 1-(10Z-heptadecenoyl)-2-
CC         (5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3-phosphoethanolamine +
CC         CoA; Xref=Rhea:RHEA:64204, ChEBI:CHEBI:57287, ChEBI:CHEBI:57368,
CC         ChEBI:CHEBI:149768, ChEBI:CHEBI:149769;
CC         Evidence={ECO:0000250|UniProtKB:Q91V01};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:64205;
CC         Evidence={ECO:0000250|UniProtKB:Q91V01};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1-O-(1Z-alkenyl)-sn-glycero-3-phosphoethanolamine +
CC         (5Z,8Z,11Z,14Z)-eicosatetraenoyl-CoA = 1-O-(1Z)-alkenyl-2-
CC         (5Z,8Z,11Z,14Z)-eicosatetraenoyl-sn-glycero-3-phosphoethanolamine +
CC         CoA; Xref=Rhea:RHEA:37635, ChEBI:CHEBI:57287, ChEBI:CHEBI:57368,
CC         ChEBI:CHEBI:77288, ChEBI:CHEBI:77295;
CC         Evidence={ECO:0000250|UniProtKB:Q91V01};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37636;
CC         Evidence={ECO:0000250|UniProtKB:Q91V01};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1-acyl-sn-glycero-3-phospho-L-serine + (9Z,12Z)-
CC         octadecadienoyl-CoA = 1-acyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-
CC         phospho-L-serine + CoA; Xref=Rhea:RHEA:37567, ChEBI:CHEBI:57287,
CC         ChEBI:CHEBI:57383, ChEBI:CHEBI:64379, ChEBI:CHEBI:75066;
CC         Evidence={ECO:0000269|PubMed:18782225};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37568;
CC         Evidence={ECO:0000305|PubMed:18782225};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1-acyl-sn-glycero-3-phospho-L-serine + (5Z,8Z,11Z,14Z)-
CC         eicosatetraenoyl-CoA = 1-acyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-
CC         glycero-3-phospho-L-serine + CoA; Xref=Rhea:RHEA:37571,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:57368, ChEBI:CHEBI:64379,
CC         ChEBI:CHEBI:75065; Evidence={ECO:0000269|PubMed:18782225};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37572;
CC         Evidence={ECO:0000305|PubMed:18782225};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-hexadecanoyl-sn-glycero-3-phospho-L-serine + (9Z)-
CC         octadecenoyl-CoA = 1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-
CC         phospho-L-serine + CoA; Xref=Rhea:RHEA:37531, ChEBI:CHEBI:57287,
CC         ChEBI:CHEBI:57387, ChEBI:CHEBI:75020, ChEBI:CHEBI:75029;
CC         Evidence={ECO:0000269|PubMed:18195019};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37532;
CC         Evidence={ECO:0000305|PubMed:18195019};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-(9Z-octadecenoyl)-sn-glycero-3-phospho-L-serine + (9Z)-
CC         octadecenoyl-CoA = 1,2-di-(9Z)-octadecenoyl-sn-glycero-3-phospho-L-
CC         serine + CoA; Xref=Rhea:RHEA:37407, ChEBI:CHEBI:57287,
CC         ChEBI:CHEBI:57387, ChEBI:CHEBI:74617, ChEBI:CHEBI:74905;
CC         Evidence={ECO:0000250|UniProtKB:Q91V01};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37408;
CC         Evidence={ECO:0000250|UniProtKB:Q91V01};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-hexadecanoyl-sn-glycero-3-phospho-L-serine + (9Z,12Z)-
CC         octadecadienoyl-CoA = 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-
CC         glycero-3-phospho-L-serine + CoA; Xref=Rhea:RHEA:37535,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:57383, ChEBI:CHEBI:75020,
CC         ChEBI:CHEBI:75031; Evidence={ECO:0000269|PubMed:18195019};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37536;
CC         Evidence={ECO:0000305|PubMed:18195019};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-(9Z-octadecenoyl)-sn-glycero-3-phospho-L-serine + (9Z,12Z)-
CC         octadecadienoyl-CoA = 1-(9Z-octadecenoyl)-2-(9Z,12Z-octadienoyl)-sn-
CC         glycero-3-phospho-L-serine + CoA; Xref=Rhea:RHEA:37375,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:57383, ChEBI:CHEBI:74617,
CC         ChEBI:CHEBI:74892; Evidence={ECO:0000269|PubMed:18772128};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37376;
CC         Evidence={ECO:0000305|PubMed:18772128};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-hexadecanoyl-sn-glycero-3-phospho-L-serine +
CC         (5Z,8Z,11Z,14Z)-eicosatetraenoyl-CoA = 1-hexadecanoyl-2-
CC         (5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3-phospho-L-serine + CoA;
CC         Xref=Rhea:RHEA:37539, ChEBI:CHEBI:57287, ChEBI:CHEBI:57368,
CC         ChEBI:CHEBI:75020, ChEBI:CHEBI:75032;
CC         Evidence={ECO:0000269|PubMed:18195019};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37540;
CC         Evidence={ECO:0000305|PubMed:18195019};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-(9Z-octadecenoyl)-sn-glycero-3-phospho-L-serine +
CC         (5Z,8Z,11Z,14Z)-eicosatetraenoyl-CoA = 1-(9Z-octadecenoyl)-2-
CC         (5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3-phospho-L-serine + CoA;
CC         Xref=Rhea:RHEA:37379, ChEBI:CHEBI:57287, ChEBI:CHEBI:57368,
CC         ChEBI:CHEBI:74617, ChEBI:CHEBI:74897;
CC         Evidence={ECO:0000269|PubMed:18772128};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37380;
CC         Evidence={ECO:0000305|PubMed:18772128};
CC   -!- ACTIVITY REGULATION: Activity is inhibited by thimerosal.
CC       {ECO:0000269|PubMed:18772128}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=41.29 uM for palmitoyl-CoA {ECO:0000269|PubMed:18195019};
CC         KM=36.65 uM for stearoyl-CoA {ECO:0000269|PubMed:18195019};
CC         KM=72.68 uM for oleoyl-CoA {ECO:0000269|PubMed:18195019};
CC         KM=201.4 uM for linoleoyl-CoA {ECO:0000269|PubMed:18195019};
CC         KM=71.56 uM for arachidonoyl-CoA {ECO:0000269|PubMed:18195019};
CC         KM=72.19 uM for 1-palmitoyl-lysophosphatidylcholine
CC         {ECO:0000269|PubMed:18195019};
CC         Vmax=1782 nmol/min/mg enzyme with palmitoyl-CoA and
CC         1-palmitoyl-lysophosphatidylcholine as substrates
CC         {ECO:0000269|PubMed:18195019};
CC         Vmax=996 nmol/min/mg enzyme with stearoyl-CoA and
CC         1-palmitoyl-lysophosphatidylcholine as substrates
CC         {ECO:0000269|PubMed:18195019};
CC         Vmax=4698 nmol/min/mg enzyme with oleoyl-CoA and
CC         1-palmitoyl-lysophosphatidylcholine as substrates
CC         {ECO:0000269|PubMed:18195019};
CC         Vmax=18148 nmol/min/mg enzyme with linoleoyl-CoA and
CC         1-palmitoyl-lysophosphatidylcholine as substrates
CC         {ECO:0000269|PubMed:18195019};
CC         Vmax=6247 nmol/min/mg enzyme with arachidonoyl-CoA and
CC         1-palmitoyl-lysophosphatidylcholine as substrates
CC         {ECO:0000269|PubMed:18195019};
CC   -!- PATHWAY: Lipid metabolism; phospholipid metabolism.
CC       {ECO:0000269|PubMed:18195019}.
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:18195019}; Multi-pass membrane protein
CC       {ECO:0000255}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q6P1A2-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q6P1A2-2; Sequence=VSP_053680;
CC   -!- TISSUE SPECIFICITY: Highly expressed in liver, pancreas and adipose
CC       tissue. Very low expression in skeletal muscle and heart. Detected in
CC       neutrophils. {ECO:0000269|PubMed:18195019,
CC       ECO:0000269|PubMed:18772128}.
CC   -!- DOMAIN: The di-lysine motif confers endoplasmic reticulum localization.
CC   -!- SIMILARITY: Belongs to the membrane-bound acyltransferase family.
CC       {ECO:0000255}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB51326.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAC51640.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAG37917.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; BX648009; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AK296145; BAH12269.1; -; mRNA.
DR   EMBL; AK315538; BAG37917.1; ALT_INIT; mRNA.
DR   EMBL; AC006512; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC000664; AAH00664.2; -; mRNA.
DR   EMBL; BC065194; AAH65194.1; -; mRNA.
DR   EMBL; U47924; AAB51326.1; ALT_INIT; Genomic_DNA.
DR   EMBL; U72515; AAC51640.1; ALT_INIT; mRNA.
DR   EMBL; BT007000; AAP35646.1; -; mRNA.
DR   CCDS; CCDS8572.1; -. [Q6P1A2-1]
DR   RefSeq; NP_005759.4; NM_005768.5. [Q6P1A2-1]
DR   AlphaFoldDB; Q6P1A2; -.
DR   SMR; Q6P1A2; -.
DR   BioGRID; 115464; 93.
DR   FunCoup; Q6P1A2; 1153.
DR   IntAct; Q6P1A2; 60.
DR   MINT; Q6P1A2; -.
DR   STRING; 9606.ENSP00000261407; -.
DR   SwissLipids; SLP:000000127; -.
DR   GlyGen; Q6P1A2; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q6P1A2; -.
DR   PhosphoSitePlus; Q6P1A2; -.
DR   SwissPalm; Q6P1A2; -.
DR   BioMuta; LPCAT3; -.
DR   DMDM; 74737127; -.
DR   jPOST; Q6P1A2; -.
DR   MassIVE; Q6P1A2; -.
DR   PaxDb; 9606-ENSP00000261407; -.
DR   PeptideAtlas; Q6P1A2; -.
DR   ProteomicsDB; 6534; -.
DR   ProteomicsDB; 66828; -. [Q6P1A2-1]
DR   Pumba; Q6P1A2; -.
DR   Antibodypedia; 67641; 74 antibodies from 12 providers.
DR   DNASU; 10162; -.
DR   Ensembl; ENST00000261407.9; ENSP00000261407.4; ENSG00000111684.11. [Q6P1A2-1]
DR   GeneID; 10162; -.
DR   KEGG; hsa:10162; -.
DR   MANE-Select; ENST00000261407.9; ENSP00000261407.4; NM_005768.6; NP_005759.4.
DR   UCSC; uc001qsi.4; human. [Q6P1A2-1]
DR   AGR; HGNC:30244; -.
DR   CTD; 10162; -.
DR   DisGeNET; 10162; -.
DR   GeneCards; LPCAT3; -.
DR   HGNC; HGNC:30244; LPCAT3.
DR   HPA; ENSG00000111684; Low tissue specificity.
DR   MIM; 611950; gene.
DR   OpenTargets; ENSG00000111684; -.
DR   VEuPathDB; HostDB:ENSG00000111684; -.
DR   eggNOG; KOG2705; Eukaryota.
DR   GeneTree; ENSGT01030000234564; -.
DR   HOGENOM; CLU_011340_6_1_1; -.
DR   InParanoid; Q6P1A2; -.
DR   OMA; NAWVSRY; -.
DR   OrthoDB; 5974730at2759; -.
DR   PAN-GO; Q6P1A2; 5 GO annotations based on evolutionary models.
DR   PhylomeDB; Q6P1A2; -.
DR   BRENDA; 2.3.1.23; 2681.
DR   PathwayCommons; Q6P1A2; -.
DR   Reactome; R-HSA-1482788; Acyl chain remodelling of PC.
DR   Reactome; R-HSA-1482801; Acyl chain remodelling of PS.
DR   Reactome; R-HSA-1482839; Acyl chain remodelling of PE.
DR   SABIO-RK; Q6P1A2; -.
DR   SignaLink; Q6P1A2; -.
DR   UniPathway; UPA00085; -.
DR   BioGRID-ORCS; 10162; 55 hits in 1166 CRISPR screens.
DR   ChiTaRS; LPCAT3; human.
DR   GeneWiki; MBOAT5; -.
DR   GenomeRNAi; 10162; -.
DR   Pharos; Q6P1A2; Tbio.
DR   PRO; PR:Q6P1A2; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   RNAct; Q6P1A2; protein.
DR   Bgee; ENSG00000111684; Expressed in right lobe of liver and 172 other cell types or tissues.
DR   ExpressionAtlas; Q6P1A2; baseline and differential.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0003841; F:1-acylglycerol-3-phosphate O-acyltransferase activity; TAS:Reactome.
DR   GO; GO:0047184; F:1-acylglycerophosphocholine O-acyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0106262; F:1-acylglycerophosphoethanolamine O-acyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0106263; F:1-acylglycerophosphoserine O-acyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0047144; F:2-acylglycerol-3-phosphate O-acyltransferase activity; TAS:Reactome.
DR   GO; GO:0071617; F:lysophospholipid acyltransferase activity; IBA:GO_Central.
DR   GO; GO:0034378; P:chylomicron assembly; ISS:UniProtKB.
DR   GO; GO:0090158; P:endoplasmic reticulum membrane organization; ISS:UniProtKB.
DR   GO; GO:0036335; P:intestinal stem cell homeostasis; ISS:UniProtKB.
DR   GO; GO:0030258; P:lipid modification; IBA:GO_Central.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; ISS:UniProtKB.
DR   GO; GO:1903573; P:negative regulation of response to endoplasmic reticulum stress; ISS:UniProtKB.
DR   GO; GO:0036151; P:phosphatidylcholine acyl-chain remodeling; IDA:UniProtKB.
DR   GO; GO:0006656; P:phosphatidylcholine biosynthetic process; IBA:GO_Central.
DR   GO; GO:0036152; P:phosphatidylethanolamine acyl-chain remodeling; IDA:UniProtKB.
DR   GO; GO:0036150; P:phosphatidylserine acyl-chain remodeling; IDA:UniProtKB.
DR   GO; GO:0045797; P:positive regulation of intestinal cholesterol absorption; ISS:UniProtKB.
DR   GO; GO:1905885; P:positive regulation of triglyceride transport; ISS:UniProtKB.
DR   GO; GO:0045540; P:regulation of cholesterol biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0034379; P:very-low-density lipoprotein particle assembly; ISS:UniProtKB.
DR   InterPro; IPR049941; LPLAT_7/PORCN-like.
DR   InterPro; IPR004299; MBOAT_fam.
DR   PANTHER; PTHR13906:SF14; LYSOPHOSPHOLIPID ACYLTRANSFERASE 5; 1.
DR   PANTHER; PTHR13906; PORCUPINE; 1.
DR   Pfam; PF03062; MBOAT; 1.
DR   neXtProt; NX_Q6P1A2; -.
DR   PharmGKB; PA162394266; -.
DR   TreeFam; TF106143; -.
PE   1: Evidence at protein level;
KW   Acetylation; Acyltransferase; Alternative splicing; Endoplasmic reticulum;
KW   Lipid biosynthesis; Lipid metabolism; Membrane; Phospholipid biosynthesis;
KW   Phospholipid metabolism; Proteomics identification; Reference proteome;
KW   Transferase; Transmembrane; Transmembrane helix.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0007744|PubMed:25944712"
FT   CHAIN           2..487
FT                   /note="Lysophospholipid acyltransferase 5"
FT                   /id="PRO_0000233382"
FT   TRANSMEM        44..64
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        84..104
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        111..131
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        180..200
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        227..247
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        285..305
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        364..384
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        422..442
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        453..473
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   MOTIF           484..487
FT                   /note="Di-lysine motif"
FT   ACT_SITE        338
FT                   /evidence="ECO:0000250"
FT   ACT_SITE        374
FT                   /evidence="ECO:0000250"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0007744|PubMed:25944712"
FT   VAR_SEQ         21..100
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_053680"
FT   VARIANT         63
FT                   /note="F -> L (in dbSNP:rs34196984)"
FT                   /id="VAR_050027"
FT   VARIANT         217
FT                   /note="I -> T (in dbSNP:rs1984564)"
FT                   /id="VAR_050028"
FT   CONFLICT        387
FT                   /note="E -> K (in Ref. 4; AAH00664 and 6; AAP35646)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   487 AA;  56035 MW;  429258B54585B4A7 CRC64;
     MASSAEGDEG TVVALAGVLQ SGFQELSLNK LATSLGASEQ ALRLIISIFL GYPFALFYRH
     YLFYKETYLI HLFHTFTGLS IAYFNFGNQL YHSLLCIVLQ FLILRLMGRT ITAVLTTFCF
     QMAYLLAGYY YTATGNYDIK WTMPHCVLTL KLIGLAVDYF DGGKDQNSLS SEQQKYAIRG
     VPSLLEVAGF SYFYGAFLVG PQFSMNHYMK LVQGELIDIP GKIPNSIIPA LKRLSLGLFY
     LVGYTLLSPH ITEDYLLTED YDNHPFWFRC MYMLIWGKFV LYKYVTCWLV TEGVCILTGL
     GFNGFEEKGK AKWDACANMK VWLFETNPRF TGTIASFNIN TNAWVARYIF KRLKFLGNKE
     LSQGLSLLFL ALWHGLHSGY LVCFQMEFLI VIVERQAARL IQESPTLSKL AAITVLQPFY
     YLVQQTIHWL FMGYSMTAFC LFTWDKWLKV YKSIYFLGHI FFLSLLFILP YIHKAMVPRK
     EKLKKME
//
